

Provided by:



Neuroendocrine Tumor Board 2023-2024 2023

Neuroendocrine Tumor Board 2023-2024 - 4/7/2023

April 7, 2023

7:00 AM - 8:00 AM

Microsoft Teams

Target Audience

This program has been designed for Dermatology, Family Medicine, Pediatrics, Internal Medicine - Advanced Heart Failure And Transplant Cardiology, Interventional Radiology And Diagnostic Radiology, Nuclear Medicine, Internal Medicine - Medical Oncology, Pathology - Clinical, Psychiatry, Radiation Oncology, Surgery, Thoracic And Cardiac Surgery, Urology, Vascular Surgery, Internal Medicine - Endocrinology, Diabetes And Metabolism, Internal Medicine - Gastroenterology, Internal Medicine, Internal Medicine - Geriatric Medicine, Internal Medicine - Nephrology, Otolaryngology, Internal Medicine - Adult Congenital Heart Disease, Internal Medicine - Cardiovascular Disease, Pathology - Anatomic, Medical Genetics And Genomics - Medical Biochemical Genetics, Laboratory Genetics And Genomics, Medical Genetics And Genomics - Molecular Genetic Pathology, Otolaryngology - Neurotology, Pediatrics - Pediatric Gastroenterology, Pediatrics - Pediatric Hematology-Oncology, Pediatrics - Pediatric Nephrology, Internal Medicine - Hospice And Palliative Medicine, Radiology , Radiology - Nuclear Radiology, Radiology - Pain Medicine, Surgery - Complex General Surgical Oncology, Surgery - Pediatric Surgery, Pathology-Anatomic/Pathology-Clinical

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss appropriate, comprehensive, multidisciplinary best practice treatment plans for NET patients and their families
- 2 Describe an in-depth knowledge of the various imaging techniques and treatment options for the diagnosis, surveillance and treatment of NET patient.
- 3 Discuss the rapidly evolving field of neuroendocrinology through analysis of best medical practices and research
- 4 Discuss how to strengthen professionalism among the multidisciplinary team participants

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact
Bonita Bennett, Maria Bonanni
(215) 349-5562, (609) 338-7824

bonita.bennett@uphs.upenn.edu, Maria.Bonanni@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Jennifer Eads, MD	Co-Director	Advisor-Advanced Accelerator Applications (Relationship has ended) - 12/08/2022
Debbie Cohen, MD	Co-Director, Faculty	Nothing to disclose - 02/17/2023
Maria Bonanni, CRNP	Faculty, Nurse Planner	Nothing to disclose - 05/10/2022
Bonita J. Bennett, BSN	Nurse Planner	Nothing to disclose - 11/22/2022
Parul Agarwal, MD	Other Planning Committee Member	Nothing to disclose - 08/01/2022
Zubair Baloch, MD, PH	Other Planning Committee Member	Nothing to disclose - 09/02/2022
Keith Cengel, MD, PhD	Other Planning Committee Member	Nothing to disclose - 12/02/2022
Roger Cohen, MD	Other Planning Committee Member	Consulting Fee-Astra Zeneca Pharmaceuticals Consulting Fee-Heat (Relationship has ended) Grant or research support-Astra Zeneca Pharmaceuticals (Relationship has ended) Grant or research support-Innate (Relationship has ended) Grant or research support-Macrogenics (Relationship has ended) Grant or research support-Fstar Grant or research support-Xencor (Relationship has ended) Consulting Fee-Cantargia Grant or

		research support-Cantargia - 11/29/2022
Nevena Damjanov, MD	Other Planning Committee Member	Nothing to disclose - 11/17/2022
Mervyn D Danilewitz, MD	Other Planning Committee Member	Nothing to disclose - 11/17/2022
Douglas Fraker, MD	Other Planning Committee Member	Nothing to disclose - 11/27/2022
Yonghong Huan, MD	Other Planning Committee Member	Nothing to disclose - 09/20/2022
Galen Leung, MD	Other Planning Committee Member	Nothing to disclose - 11/21/2022
Virginia A LiVolsi, MD	Other Planning Committee Member	Nothing to disclose - 09/07/2022
Ryan Massa, MD	Other Planning Committee Member	Nothing to disclose - 11/17/2022
Katherine L Nathanson, MD	Other Planning Committee Member	Advisor-Merck & Co (Relationship has ended) - 11/30/2022
Sophia O'Brien, MD	Other Planning Committee Member	Nothing to disclose - 11/30/2022
Daniel Pryma, MD	Other Planning Committee Member	Consulting Fee-Progenics (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-MTTI Stocks or stock options, excluding diversified mutual funds-MTTI Membership on Advisory Committees or Review Panels, Board Membership, etc.-Trevarx Stocks or stock options, excluding diversified mutual funds-Trevarx Consulting Fee-Curium (Relationship has ended) Consulting Fee-Siemens Medical Solutions, Inc. (Relationship has ended) Consulting Fee-Bayer (Relationship has ended) - 12/01/2022
Christopher Rassekh, MD	Other Planning Committee Member	Consulting Fee-Medtronic Consulting Fee-Cook Medical - 01/13/2023
Robert E Roses, MD	Other Planning Committee Member	Nothing to disclose - 04/15/2022
Charles Schneider, MD	Other Planning Committee Member	Nothing to disclose - 11/22/2022
Aditi Singh, MD	Other Planning Committee Member	Nothing to disclose - 09/23/2022
Michael Soulen, MD	Other Planning Committee Member	Grant or research support-Guerbet LLC Grant or research support-Pfizer, Inc. Grant or research support-Sirtex Consulting Fee-Guerbet LLC Consulting Fee-Instylla (Relationship has ended) Advisor-Genentech (Relationship has ended) Advisor-Astra Zeneca Pharmaceuticals (Relationship has

		ended) - 11/18/2022
Ursina Teitelbaum, MD	Other Planning Committee Member	Nothing to disclose - 12/11/2022
Heather Wachtel, MD	Other Planning Committee Member	Nothing to disclose - 07/11/2022
Heather Warren, RN	Other Planning Committee Member	Nothing to disclose - 12/01/2022
Zhaohai Yang, MD, PhD	Other Planning Committee Member	Consulting Fee-Vertex pharmaceuticals Grant or research support-Castle bioscience (Relationship has ended) - 10/26/2022

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.